HK Stock Movement | REMEGEN (09995) Rises Over 7% in Afternoon Session as Telitacicept Gains Rapid Traction and Disitamab Vedotin Shows Superior Efficacy in Combination Therapy

Stock News11-27

REMEGEN (09995) surged more than 7% in the afternoon session, reaching a 6.39% increase at press time to HK$90.75, with a trading volume of HK$319 million.

According to reports, at the 2025 ESMO Annual Meeting, Phase III clinical trial results were released for disitamab vedotin combined with toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. Yongxing Securities noted that the combination therapy demonstrated outstanding efficacy, signaling a major shift in urothelial carcinoma treatment.

CITIC Securities highlighted that in 2025, REMEGEN's core product telitacicept is expected to see rapid sales growth following the approval of new indications, while disitamab vedotin's combination therapy continues to deliver strong clinical data. Additionally, the marketing application for RC28 in diabetic macular edema (DME) has been accepted. Among its pipeline, RC148 received Breakthrough Therapy designation, further validating its clinical potential.

Overall, the company's commercialization efforts are accelerating, supported by a well-structured pipeline, reinforcing positive prospects for future growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172011622?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-27 13:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172011622","market":"hk","top_or_hot":-1,"title":"HK Stock Movement | REMEGEN (09995) Rises Over 7% in Afternoon Session as Telitacicept Gains Rapid Traction and Disitamab Vedotin Shows Superior Efficacy in Combination Therapy","media":"Stock News","content":"<p>REMEGEN (09995) surged more than 7% in the afternoon session, reaching a 6.39% increase at press time to HK$90.75, with a trading volume of HK$319 million.</p>\n<p>According to reports, at the 2025 ESMO Annual Meeting, Phase III clinical trial results were released for disitamab vedotin combined with toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. Yongxing Securities noted that the combination therapy demonstrated outstanding efficacy, signaling a major shift in urothelial carcinoma treatment.</p>\n<p>CITIC Securities highlighted that in 2025, REMEGEN's core product telitacicept is expected to see rapid sales growth following the approval of new indications, while disitamab vedotin's combination therapy continues to deliver strong clinical data. Additionally, the marketing application for RC28 in diabetic macular edema (DME) has been accepted. Among its pipeline, RC148 received Breakthrough Therapy designation, further validating its clinical potential.</p>\n<p>Overall, the company's commercialization efforts are accelerating, supported by a well-structured pipeline, reinforcing positive prospects for future growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | REMEGEN (09995) Rises Over 7% in Afternoon Session as Telitacicept Gains Rapid Traction and Disitamab Vedotin Shows Superior Efficacy in Combination Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | REMEGEN (09995) Rises Over 7% in Afternoon Session as Telitacicept Gains Rapid Traction and Disitamab Vedotin Shows Superior Efficacy in Combination Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-27 13:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>REMEGEN (09995) surged more than 7% in the afternoon session, reaching a 6.39% increase at press time to HK$90.75, with a trading volume of HK$319 million.</p>\n<p>According to reports, at the 2025 ESMO Annual Meeting, Phase III clinical trial results were released for disitamab vedotin combined with toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. Yongxing Securities noted that the combination therapy demonstrated outstanding efficacy, signaling a major shift in urothelial carcinoma treatment.</p>\n<p>CITIC Securities highlighted that in 2025, REMEGEN's core product telitacicept is expected to see rapid sales growth following the approval of new indications, while disitamab vedotin's combination therapy continues to deliver strong clinical data. Additionally, the marketing application for RC28 in diabetic macular edema (DME) has been accepted. Among its pipeline, RC148 received Breakthrough Therapy designation, further validating its clinical potential.</p>\n<p>Overall, the company's commercialization efforts are accelerating, supported by a well-structured pipeline, reinforcing positive prospects for future growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1574","symbol_name":"生物医药B类股","start_time":0,"source_url":"","article_id":"1172011622","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172011622","pubTimestamp":1764222433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"REMEGEN (09995) surged more than 7% in the afternoon session, reaching a 6.39% increase at press time to HK$90.75, with a trading volume of HK$319 million. According to reports, at the 2025 ESMO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688331":"荣昌生物","BK1574":"生物医药B类股","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","09995":"荣昌生物","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK0239":"医药制造","BK1583":"高瓴概念","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","BK1161":"生物科技"},"translate_title":"港股动向|瑞美根(09995)午后涨超7%，泰利他西普快速获追捧，维迪西单抗联合疗法疗效卓越","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688331":1,"09995":1},"content_text":"REMEGEN (09995) surged more than 7% in the afternoon session, reaching a 6.39% increase at press time to HK$90.75, with a trading volume of HK$319 million.\nAccording to reports, at the 2025 ESMO Annual Meeting, Phase III clinical trial results were released for disitamab vedotin combined with toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma. Yongxing Securities noted that the combination therapy demonstrated outstanding efficacy, signaling a major shift in urothelial carcinoma treatment.\nCITIC Securities highlighted that in 2025, REMEGEN's core product telitacicept is expected to see rapid sales growth following the approval of new indications, while disitamab vedotin's combination therapy continues to deliver strong clinical data. Additionally, the marketing application for RC28 in diabetic macular edema (DME) has been accepted. Among its pipeline, RC148 received Breakthrough Therapy designation, further validating its clinical potential.\nOverall, the company's commercialization efforts are accelerating, supported by a well-structured pipeline, reinforcing positive prospects for future growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172011622","isCrawlerRequest":true}